For Wyeth, More Delays And Setbacks
Phase III methylnaltrexone study fails to show benefit over placebo, as Wyeth also pulls Pristiq’s EU vasomotor symptoms application.
Phase III methylnaltrexone study fails to show benefit over placebo, as Wyeth also pulls Pristiq’s EU vasomotor symptoms application.